Clinical Trial Update: Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis [Phase 2]

View source ↗

Summary

Phase 2 trial comparing sorafenib plus hepatic arterial infusion versus sorafenib alone in hepatocellular carcinoma with major portal vein tumor thrombosis has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Portal Vein Thrombosis

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Peking University | Conditions: HepatoCellular Carcinoma, Portal Vein Thrombosis | Phase 2 | Status: COMPLETED